



3rd International Geriatric Diabetes Workshop Agenda

PHARMACOTHERAPY IN OLDER ADULTS

OCTOBER 31 – NOVEMBER 1, 2022 | BOSTON, MA, USA

OCTOBER 31: MONDAY

8.00 – 8.10: **WELCOME AND OVERVIEW**
Medha Munshi

8.10 – 10.00: **SESSION 1: BROAD OVERVIEW OF DIABETES MANAGEMENT IN OLDER ADULTS**
Chair: Alan Sinclair

8.10 – 8.15: **Introduction**

8.20 – 8.35: **Impact of hypo- and hyperglycemia on older adults**
Ruth Weinstock
SUNY Upstate Medical University, USA

8.40 – 8.55: **What do we know about the benefits and risks of tight glycemic control in older adults?**
Paul Conlin
VA Boston Healthcare System
Harvard Medical School, USA

9.00 – 9.15: **Current guidelines for the use of glucose-lowering agents in older adults**
Elbert Huang
University of Chicago, USA

9.20 – 9.35: **Gaps in current guidelines**
Sei Lee
University of California, San Francisco, USA

9.40 – 10.05: **Group discussion**

10.05 – 10.15: **COFFEE BREAK**

10.15 – 12.30: **SESSION 2: DIFFERENT CLASSES OF GLUCOSE-LOWERING AGENTS IN OLDER ADULTS**
Chair: Grady Meneilly

10.15 – 10.20: **Introduction**

10.25 – 10.40: **Use of other (older) medications (metformin, sulfonylurea, TZDs) in older adults**
Jeff Halter
National University of Singapore
University of Michigan, USA

3RD INTERNATIONAL GERIATRIC DIABETES WORKSHOP AGENDA

OCTOBER 31: MONDAY (cont.)

10.45 – 11.15: **DPP4 and SGLT-2 inhibitors in older adults**

Om Ganda
Joslin Diabetes Center
Harvard Medical School, USA

11.20 – 11.35: **GLP-1RA in older adults**

Rich Pratley
AdventHealth Diabetes Institute, USA

11.40 – 11.55: **Use of insulin therapy in older adults with T2D**

Elena Toschi
Joslin Diabetes Center
Harvard Medical School, USA

11.55- 12.30 **Group Discussion**

12.30-1.30 **LUNCH**

1.30 – 3.20: **SESSION 3: COMORBIDITIES AND CONDITIONS FOR CONSIDERATION FOR GLUCOSE-LOWERING THERAPY IN OLDER ADULTS**

Chair: Elbert Huang

1.30 – 1.35: **INTRODUCTION**

1.40 – 1.55: **Burden of CVD and CKD in older adults -Role of risk factor reduction in older adults**

Carol Wysham
MultiCare Rockwood Clinic Endocrinology & Diabetes Education, Washington, USA

2.00 – 2.15: **Cognitive function and its relationship with glucose-lowering agents**

Tali Cukierman-Yaffe
Sheba Medical Center, Sackler School of Medicine, Herczeg Institute on Aging
Tel-Aviv University, Israel

2.20 – 2.35: **Frailty and its relationship with glucose-lowering agents**

Stefano Volpato
University of Ferrara, Italy

2.40 – 2.55: **Other important comorbidities and polypharmacy and their relationship with glucose-lowering agents**

Viral Shah
University of Colorado, USA

2.55 – 3.20: **Group discussion**

3.20 – 3.30: **COFFEE BREAK**

3.30 – 5.30: **SESSION 4: GLUCOSE-LOWERING THERAPY IN OLDER ADULTS WITH T1D**

Chair: Rich Pratley

3.30 – 3.35: **Introduction**

3.40 – 3.55: **Demographics and characteristics of older adults with T1D**

Anna Kahkoska
University of North Carolina, USA

3RD INTERNATIONAL GERIATRIC DIABETES WORKSHOP AGENDA

OCTOBER 31: MONDAY (cont.)

4.00 – 4.15: **Insulin therapy – intensification and deintensification**

Lori Laffel
Joslin Diabetes Center
Harvard Medical School, USA

4.20 – 4.35: **Hybrid closed loop systems in older adults with T1D**

Irl Hirsch
University of Washington, USA

4.40 – 4.55: **Optimal TIR in older adults with T1D**

David O'Neal
University of Melbourne, Australia

4.55 – 5.30: **Group discussion**

6.00 – 9.00: **DINNER**

NOVEMBER 1: TUESDAY

8.00 – 8.10: **MESSAGE FROM THE LEADER OF THE OLDER ADULT INTEREST GROUP SECTION AT THE AMERICAN DIABETES ASSOCIATION**

Chair: Ruth Weinstock

8.10 – 9.35: **SESSION 5: REAL WORLD DATA REGARDING DIABETES MANAGEMENT IN OLDER ADULTS**

Chair: Tali Cukierman-Yaffe

8.10 – 8.15: **Introduction**

8.20 – 8.35: **Perspectives from Abbott**

8.40 – 8.55: **Perspectives from Medtronic**

9.00 – 9.15: **Perspectives from Sanofi**

9.15 – 9.35: **Group Discussion**

9.35 – 9.45: **COFFEE BREAK**

9.45 – 11.30: **SESSION 6: PRINCIPLES OF THE MANAGEMENT OF DIABETES IN OLDER ADULTS: BEYOND GLYCEMIC CONTROL**

Chair: Sei Lee

9.45 – 9.50: **Introduction**

9.55- 10.10: **Prediabetes and new onset diabetes: new evidence and should it be treated in older adults? And with what medications?**

Grady Meneilly
University of British Columbia, Vancouver, Canada

10.15-10.30: **Modern glucose-lowering therapy: Factors which influence effective target setting**

Alan Sinclair
Foundation for Diabetes Research in Older People, Diabetes Frail
England

3RD INTERNATIONAL GERIATRIC DIABETES WORKSHOP AGENDA

NOVEMBER 1: TUESDAY (cont.)

10.35 - 10.50 **De-escalation of therapy – oral agents and insulin in T1D and T2D**

Medha Munshi
Joslin Diabetes Center
Harvard Medical School, USA

10.55-11.10 **Disease management: leveraging technology in algorithms of glucose-lowering agents**

Tali Cukierman-Yaffe
Sheba Medical Center, Sackler School of Medicine, Herczeg Institute on Aging
Tel-Aviv University, Israel

11.10 -11.30 **Group Discussion**

11.30-12.00 **LUNCH**

12.00-1.30: **SESSION 7: USE OF GLUCOSE-LOWERING AGENTS IN SPECIAL CIRCUMSTANCES AND CARE SETTINGS**

Chair: Naushira Pandya

12.00-12.05 **Introduction**

12.10-12.25 **Glucose-lowering agents used for hospitalized older adults at various levels of care**

Guillermo Umpierrez
Emory University, USA

12.30-12.45 **Goals and strategies for the use of different classes of glucose-lowering medications for PA-LTC**

Naushira Pandya
Nova Southeastern University College of Osteopathic Medicine, USA

12.50-1.05 **Goals and strategies for the use of different classes of glucose-lowering medications for hospice, end-of-life care**

Diana Sherifali
McMaster University, Canada

1.10-1.30 **Group Discussion**

1.30-2.00: **CLOSING REMARKS AND FUTURE PLANNING**

**THANK YOU TO THE GENEROUS SUPPORT
FROM OUR SPONSORS:**

PLATINUM



Abbott

SILVER



ADDITIONAL SUPPORT

Medtronic